iBio: EcoR1 reports 1.58M shares (4.6%)
iBio, Inc. Schedule 13G/A shows EcoR1 Capital, LLC and related reporting persons beneficially own 1,583,000 shares of Common Stock, representing 4.6% of the class.
Rhea-AI Filing Summary
iBio, Inc. Schedule 13G/A shows EcoR1 Capital, LLC and related reporting persons beneficially own 1,583,000 shares of Common Stock, representing 4.6% of the class. The filing states the calculation is based on 34,543,561 shares outstanding as of February 9, 2026.
The filing lists shared voting and dispositive power for the reported positions and clarifies EcoR1 is the general partner of the funds while Oleg Nodelman is the control person. Signatures show the filing was executed on May 14, 2026.
Positive
- None.
Negative
- None.
Insights
EcoR1 reports a sub-5% stake in iBio, disclosed via Schedule 13G/A.
The statement records 1,583,000 shares and a 4.6% ownership percentage using an outstanding share base of 34,543,561 shares as of February 9, 2026. The reported holdings are shown as shared voting and dispositive power, consistent with a fund/manager structure.
Cash‑flow treatment and any planned transactions are not stated; subsequent filings would show changes. Holder decisions and future disclosures will determine whether this position remains passive or becomes active.
Filing emphasizes passive intent and joint filing mechanics.
The filing includes a signed certification that the securities were "not acquired and are not held for the purpose of or with the effect of changing or influencing the control" of the issuer. It also disclaims group membership while describing EcoR1 as general partner and Mr. Nodelman as control person.
Investors may note the ownership below 5% threshold; any future change in intent or aggregation would require amended disclosures under applicable rules.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficially owned regulatory
FAQ
What stake does EcoR1 report in iBio (IBIO)?
Who besides EcoR1 is named on the Schedule 13G/A for IBIO?
Does the Schedule 13G/A state EcoR1 seeks control of iBio?
AI-generated analysis. How Rhea-AI works. Not financial advice.